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1. Introduction 
The concept of targeting tumor blood vessel formation, i.e. tumor angiogenesis, has long 
been accepted as a potential strategy for controlling tumor growth. Characterized by the 
ability to supply oxygen, growth factors, hormones and nutrients, tumor vasculature has 
been identified as a key factor for the maintenance and progression of many solid tumors. 
The development of tumor vasculature is regulated by a highly complex network of signal 
transduction pathways involving pro- and anti-angiogenic factors. This delicate, yet 
dynamic balance between the promotion and inhibition of vascularization provides an 
abundance of molecular targets for therapeutic intervention.  
Since more than 85% of cancer mortality results from solid tumors, the continual 
development of anti-vascular agents remains an important goal in the quest for novel anti-
cancer therapies (Jain, 2005). Despite its supporting role in the nutrition and viability of 
human cancers, however, tumor angiogenesis was not always considered a hallmark of 
tumor progression (Hanahan & Folkman, 1996). Initial skepticism centered on the 
hypothesis that angiogenesis was only critical in the early phase of tumor development. 
Thus, many opponents believed that angiogenic inhibition would be largely ineffective in 
most late-stage cancers. Other skeptics argued that the concept of anti-angiogenic therapy 
was counterintuitive because destruction of the tumor vasculature would significantly 
compromise the delivery of cytotoxic agents to the tumor (Jain, 2005). Though these 
concerns are not without merit, an overwhelming body of evidence in early-stage and 
established tumors demonstrates a synergistic effect when inhibitors of angiogenesis are 
combined with chemotherapy and/or radiotherapy.  
Despite the advantages of anti-angiogenic therapy, some have proposed that vascular 
destruction promotes the increased adaptation of tumor cells to areas of insufficient 
vascularization. The basis for this concern can be found through closer examination of the 
vascular abnormalities often identified in the tumor microenvironment. Characterized by 
aberrant morphology and increased compression of blood and lymphatic vessels, the tumor 
vascular network is an environment of interstitial hypertension and hypoxia (low oxygen 
availability) (Hanahan & Folkman, 1996; Jain, 2005). While some cancer cells are able to 
survive these harsh conditions of nutrient deprivation and impaired oxygenation, many of 
these tumor cells undergo programmed cell death. Nevertheless, anti-vascular therapy is 
feared to select for tumor cells with enhanced invasive and metastatic potential. Equipped 
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with a more malignant phenotype characterized by high degrees of resilience, such tumor 
cells could plausibly disseminate into surrounding tissue and co-opt preexisting vessels that 
are resistant to angiogenesis inhibitors. Appropriately, an extensive number of studies have 
been conducted to address this issue. Fortunately, data collected from a variety of research 
groups indicate that the expansion of metastatic tumor cells to distant organ sites is 
predominantly dependent on angiogenesis (Hanahan & Folkman, 1996). Thus, 
pharmacological intervention with tumor angiogenic processes may still prove to be an 
effective method for controlling metastatic growth. 
Tumor blood vessel formation is a highly dynamic process that is regulated by a balance of 
pro- and anti-angiogenic factors. The search for angiogenic inducers first began after the 
initial observation that capillary growth was stimulated even when tumors were implanted 
into avascular regions such as the cornea. This evidence of capillary sprouting in areas of 
absent or quiescent vasculature bolstered the hypothesis that tumor cells release diffusible 
triggers of vascularization.  
The first discovered inducer of angiogenesis was basic fibroblast growth factor, known as 
bFGF or FGF-2 (Hanahan & Folkman, 1996). FGF-2 was soon accompanied by the isolation 
of the closely related FGF-1 or acidic FGF (aFGF). Although both proteins lack traditional 
signal sequences for secretion, each growth factor can be released upon exposure to cell 
stress. One angiogenic protein that is readily secreted from tumor cells is vascular 
endothelial growth factor (VEGF). Originally identified as vascular permeability factor 
(VPF), VEGF is a potent promoter of tumor vascularization and is a primary target of anti-
angiogenic therapy. Other promoters of angiogenesis include angiopoietins and members of 
the Ephrin family of ligands.  
Over the years, a number of pro-angiogenic factors have been discovered. Since 
physiological blood vessel formation is well-coordinated and tightly controlled, experts 
within the field hypothesized that tumor angiogenesis may also be a balance of pro- and 
anti-angiogenic factors. Experiments designed to address the existence of endogenous 
inhibitors of angiogenesis revealed that the mutational inactivation of a tumor suppressor 
gene initiated tumorigenesis in a previously nontumorigenic hamster cell line (Rastinejad et 
al., 1989). A secreted glycoprotein that mediates cell-cell interaction, thrombospondin-1 
(TSP-1) was shown to strongly inhibit endothelial cell chemotaxis as well as vascularization 
of the cornea. Interestingly, the regulation of TSP-1 levels is dependent on the tumor 
suppressor protein p53; TSP-1 production is dramatically lower in cells with impaired p53 
function (Rastinejad et al., 1989). This intricate relationship between tumor suppressors and 
regulators of angiogenesis further emphasizes the pivotal role of vascularization in tumor 
progression. 
Although both truncated and full-length TSP-1 can strongly attenuate vascular formation, 
many other negative regulators of angiogenesis remain sequestered as inactive components 
of larger molecules (Hanahan & Folkman, 1996). Upon receipt of the signal to limit or 
terminate vascular growth, potent inhibitory fragments of intact molecules are then 
released. An example of this quiescent storage can be found in fibronectin. Despite its 
abundance in the circulatory system, full-length fibronectin is not an inhibitor of 
angiogenesis. However, a 29 kDa fragment of the intact molecule substantially inhibited 
endothelial cell proliferation. Similarly, a 16 kDa fragment of prolactin and a fragment of 
plasminogen known as angiostatin are highly effective inhibitors of the angiogenic process.  
This pattern of storing inhibitory fragments within physiologically abundant proteins 
represents a key mechanism by which angiogenic processes can be turned on or off. In 
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addition, overwhelming evidence suggests that the balance of inducers and inhibitors is 
critical for promoting vascular quiescence over new capillary formation (Figure 1) (Hanahan 
& Folkman, 1996). Not surprisingly, a primary focus within the field of tumor angiogenesis 
is to prevent the angiogenic switch through the modulation of endogenous factors. 
 
 
Fig. 1. Controlling the Angiogenic Switch (Hanahan & Folkman, 1996).  
Both positive and negative regulators control the balance between normal quiescent 
vasculature and active blood vessel formation. Enhanced levels of pro-angiogenic molecules 
(“Pro”, green) in combination with reduced levels of anti-angiogenic molecules (“Anti”, red) 
activate the angiogenic switch. Alternatively, a reduction in the pro-angiogenic factors with 
an accompanying increase in angiogenesis inhibitors blocks neovascularization.  
In addition to their active involvement in the response to cytotoxic therapies, tumor vascular 
endothelial cells are also preferred targets due to their genetic stability. In contrast to tumor 
cells, which harbor a wide variety of genetic alterations, cytogenetic abnormalities within 
tumor endothelium are fairly limited. This substantial lack of mutations renders the tumor 
vasculature network less susceptible to acquired drug resistance (Kerbel, 1991). 
2. Response of tumor vasculature to radiation therapy 
Since its inception, anti-angiogenic therapy has evolved from a relatively unclear concept to 
a widely-accepted strategy for restricting tumor progression. The inhibition of tumor 
neovascularization has uncovered a new role for vascular endothelial cells as active 
participants in the response to conventional treatments such as chemotherapy and ionizing 
radiation. Today, anti-angiogenesis therapy is recognized as a standard modality of cancer 
treatment in addition to surgery and cytotoxic therapies. 
A potential role for vascular endothelial cells in the response to radiation therapy is 
particularly relevant for radioresistant cancers. Administered to two thirds of all cancer 
patients, ionizing radiation induces DNA damage in rapidly dividing tumor cells, causing 
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them to undergo mitotic catastrophe or apoptotic cell death. Although modifications in 
therapeutic protocols have improved tumor response, local recurrence presents an ongoing 
challenge for treatment-resistant tumors like lung cancer and glioblastoma (GBM) (Clamon 
et al., 1999; DeAngelis, 2001; Lee et al., 1999; Wagner, 2000). Both tumors are quite 
recalcitrant to radiation, and treatment of these malignancies is, therefore, highly 
problematic. Attempts to improve the treatment efficacy in GBM patients have yielded 
intensified forms of radiotherapy including brachytherapy and radioactive seeds implanted 
in the tumor bed that deliver an additional dose of radiation (up to 60 Gy). Unfortunately, 
none have significantly improved survival (DeAngelis, 2001; Suh & Barnett, 1999; Videtic et 
al., 1999). Brachytherapy has been replaced by noninvasive stereotactic radiosurgery, which 
alleviates many of the complications involved in the administration of radiation. However, 
stereotactic radiosurgery is only amenable to tumors 3 cm or less in diameter, and only if 
they are not located immediately adjacent to critical structures such as the optic nerve or 
brain stem (Tokuuye et al., 1998). Despite aggressive treatment, most glioblastoma patients 
die of the disease, with median survival of about one year.  
Poor overall survival also remains a concern for lung cancer. Despite surgery and radiation 
treatment, approximately 30 to 40% of patients with non–small-cell lung cancer (NSCLC) 
who have discrete lesions and histologically negative lymph nodes die of recurrent disease 
(Brock et al., 2008; Hoffman et al., 2000). It has become obvious, therefore, that additional 
treatments are necessary to achieve improved survival benefit for these patients. Currently, 
the most common approach to enhance the efficiency of radiotherapy is to combine 
radiation with chemotherapeutic agents (Dietz et al., 2008; Forastiere et al., 2006; Iranzo et 
al., 2009; McGinn et al., 1996; Stratford, 1992). Regrettably, many of the platinum-based 
chemotherapeutic agents used as standard treatment for cancer also exhibit toxicity within 
normal tissues. Therefore, the development of non-toxic, yet effective molecular-targeted 
radiosensitizers may have a positive impact on the therapeutic ratio.  
Understanding the response of the tumor microenvironment to ionizing radiation is 
fundamental for the design of novel and efficient radiosensitizing agents. The effectiveness of 
radiotherapy is often limited by the response of tumor vasculature, specifically vascular 
endothelium. Several studies have demonstrated that clinically relevant doses of ionizing 
radiation (2-5 Gy) elicit the activation of both PI3K/Akt and MAPK pro-survival signaling 
pathways in vascular endothelium (Dent et al., 2003; Linkous et al., 2009; Yazlovitskaya et al., 
2008; Zhan & Han, 2004; Zingg et al., 2004). The result of such activation is increased 
radioresistance within the tumor blood vessels. Since destruction of the tumor vascular 
network enhances the treatment of cancer (Folkman, 1971; Strijbos et al., 2008), radiosensitizers 
that target these survival pathways could improve the outcome of cancer patients.  
Upon irradiation, signal transduction is generated during the interaction of ionizing 
radiation with cellular membranes (Haimovitz-Friedman et al., 1994; Valerie et al., 2007). In 
our laboratory, we demonstrated that ionizing radiation interacts with vascular endothelial 
cell membranes to activate an enzyme known as cytosolic phospholipase A2 (cPLA2) (Figure 
2) (Linkous et al., 2009; Yazlovitskaya et al., 2008). As an 85-kDa Ca2+-sensitive protein, 
cPLA2 belongs to a superfamily of PLA2 enzymes that are responsible for the hydrolysis of 
the sn-2 acyl bond of glycerophospholipids on the cell membrane. As a result of this 
hydrolysis, both free fatty acid and lysophospholipids are generated. Calcium binding to the 
amino-terminal CalB domain of cPLA2 promotes the translocation of the ubiquitously 
distributed cPLA2 from the cytosol to the cell membrane. Once there, cPLA2 then specifically 
cleaves the acyl ester bond of phosphatidylcholine (PC) to produce lysophospholipids and 
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release arachidonic acid (AA) (Hirabayashi et al., 1999; Hirabayashi et al., 2004; Hirabayashi 
& Shimizu, 2000).  
 
 
Fig. 2. Proposed sequence of molecular events in irradiated vascular endothelium 
(Yazlovitskaya et al., 2008). (a) Ionizing radiation triggers the activation of cytosolic 
phospholipase A2 (cPLA2) followed by increased production of lysophosphatidylcholine 
(LPC), activation of Flk-1 (VEGFR-2) and phosphorylation of Akt and extracellular signal-
regulated kinase (ERK) 1/2 leading to cell viability. (b) Inhibition of this survival pathway at 
the level of various components (indicated by crosses) leads to cell death, decreased 
endothelial function, and increased radiosensitization.  
This cytosolic form of PLA2 has been implicated in diverse cellular responses such as 
mitogenesis, differentiation, and inflammation. Radiation-induced activation of cPLA2 in 
vascular endothelial cells resulted in the increased production of LPC, a lipid-derived 
second messenger which triggered Akt and ERK1/2 phosphorylation (Linkous et al., 2009; 
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Yazlovitskaya et al., 2008). Influencing a wide range of cell types within the vascular system, 
LPC can modulate a variety of biological functions including cytokine synthesis, 
chemotaxis, and endothelial growth factor expression (Fujita et al., 2006). Not surprisingly, 
radiation-induced activation of the cPLA2-LPC signaling cascade contributes to the survival 
and overall radioresistance of vascular endothelial cells (Figure 2).  
Additional evidentiary support for a direct role of tumor endothelial cells in the response to 
radiation therapy was demonstrated in irradiated MCA/729 fibrosarcomas and B16F1 
melanomas (Garcia-Barros et al., 2003). Using mice deficient in acid sphingomyelinase and 
Bax, two major participants of programmed cell death, Garcia-Barros et al. demonstrated 
that, due to lack of endothelial apoptosis in the host component, tumors grew 200-400% 
more rapidly than tumors containing wild-type vasculature. In addition, tumors implanted 
in apoptosis-resistant mice were refractory to single-dose radiation up to 20 Gy (Garcia-
Barros et al., 2003).  
3. Targeting the VEGF-VEGFR pathway 
Without question, the most widely studied and well-known target of anti-angiogenesis 
therapy is VEGF. The mammalian VEGF-related family of angiogenic and lymphangiogenic 
growth factors consists of five glycoproteins referred to as VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, and placental growth factor 1 and 2 (PGF-1 and PGF-2) (Ellis & Hicklin, 2008; 
Hicklin & Ellis, 2005). Existing in both soluble and extracellular matrix-bound forms, VEGF 
promotes endothelial cell growth, migration, and survival in a variety of human cancers 
including breast, colorectal, and glioblastoma multiforme (GBM).  
Predominantly produced by tumor cells, VEGF ligands exert their pro-angiogenic effects on 
endothelial cells through the binding and activation of receptor tyrosine kinases known as 
VEGFR-1, VEGFR-2, and VEGFR-3. Each of the VEGF family ligands has a specific binding 
affinity for the different receptor tyrosine kinases. VEGF-A binds to both VEGFR-1 and 
VEGFR-2, while VEGF-B binds exclusively to VEGFR-1. VEGF-C and VEGF-D preferentially 
bind to VEGFR-3, however, proteolytic processing allows both family members to bind to 
VEGFR-2 as well (Ellis & Hicklin, 2008). Thus, members of the same glycoprotein family are 
responsible for a diverse range of functions. Since the interaction of VEGF ligands with their 
respective receptors can trigger the activation of multiple signaling pathways, the VEGF-
VEGFR axis has become the most heavily targeted pathway in anti-angiogenesis therapy 
(Ellis & Hicklin, 2008; Hicklin & Ellis, 2005).  
Initial approaches to impair VEGF-VEGFR signaling focused on the development of 
neutralizing antibodies to VEGF ligands. Attempts at pharmacological intervention have led 
to the discovery of a humanized monoclonal antibody known as bevacizumab (Table 1). 
Recognized for its ability to bind and sequester circulating VEGF-A, bevacizumab was 
recently approved by the US Food and Drug Administration (FDA) for the clinical treatment 
of patients with glioma and cancers of the colon, lung, and breast. Additional treatments 
including sorafenib and sunitinib (inhibitors of VEGF receptor tyrosine kinases) are also 
currently approved for cancer therapy (Ellis & Hicklin, 2008; Hicklin & Ellis, 2005). 
Data collected from human glioma specimens has shown a direct correlation between 
VEGF-A production and degree of malignancy; VEGF-A levels are 10 times higher in high-
grade tumors in comparison to low-grade glioma (Linkous & Yazlovitskaya, 2011; Norden 
et al., 2009; Plate et al., 1994; Plate et al., 1992; Schmidt et al., 1999). In addition, other 
principal contributors like neuropilins and angiopoietin-2 (ANG-2) promote angiogenesis 
through the potentiation of VEGF signaling.  
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Angiogenic Target Inhibitors Treated Cells or Tumors References 
VEGF-A Bevacizumab Glioma, colon cancer, lung 
cancer, and breast cancer 
(Ellis & Hicklin, 2008; 
Hicklin and Ellis, 2005) 
VEGF receptor 
tyrosine kinases 
Sorafenib 
 
Renal cell carcinoma, 
glioma, colon cancer, lung 
cancer, and breast cancer 
(Bhargava & Robinson, 
2011; Ellis & Hicklin, 2008; 
Hicklin & Ellis, 2005) 
VEGF receptor 
tyrosine kinases 
Sunitinib Renal cell carcinoma, 
glioma, colon cancer, lung 
cancer, and breast cancer 
(Bhargava & Robinson, 
2011; Ellis & Hicklin, 2008; 
Hicklin & Ellis, 2005) 
VEGF receptor 
tyrosine kinases 
Tivozanib Renal cell carcinoma, 
metastatic breast cancer, 
and advanced colorectal 
cancer 
(Bhargava & Robinson, 
2011) 
VEGF receptor 
tyrosine kinases 
Axitinib Lung cancer, metastatic 
breast cancer, pancreatic 
cancer, and advanced 
gastric cancers 
(Bhargava & Robinson, 
2011) 
Protein kinase D1-3 
(PKD1, PKD2, and 
PKD3) 
CRT0066101 Pancreatic cancer (LaValle et al., 2010) 
Rho-associated 
coiled-coil-forming 
kinase (ROCK) 
HA1077 (Fasudil) Vascular endothelial cells, 
breast cancer, and 
metastatic lung cancer 
(van der Meel et al., 2011) 
Rac1 NSC23766 T-cell lymphoma and 
prostate cancer 
(van der Meel et al., 2011) 
Cytosolic 
phospholipase A2 
(cPLA2) 
Arachidonyltrifluorometh
yl Ketone (AACOCF3) 
Vascular endothelial cells, 
mouse models of lung and 
ovarian cancers 
(Yazlovitskaya et al., 2008; 
Linkous et al., 2009; Schulte 
et al., 2011; Farooqui et al., 
2006) 
Cytosolic 
phospholipase A2 
(cPLA2) 
Methyl Arachidonyl 
Fluorophosphonate 
(MAFP) 
Vascular endothelial cells (Yazlovitskaya et al., 2008; 
Farooqui et al., 2006) 
Cytosolic 
Phospholipase A2 
(cPLA2) 
4-[2-[5-Chloro-1-
(diphenylmethyl)-2-
methyl-1H-indol-3-yl]-
ethoxy] benzoic acid 
(CDIBA) 
Vascular endothelial cells; 
mouse models of lung 
cancer and glioblastoma 
(Linkous et al., 2010) 
Autotaxin (ATX) 
and 
Lysophosphatidic 
acid (LPA) 
receptors 
BrP-LPA Breast cancer and non-
small cell lung cancer 
(Prestwich et al., 2008; 
Zhang et al., 2009) 
Enhancer of Zeste 
Homolog 2 (EZH2)
3-deazaneplanocin 
(DZNep) 
Breast cancer, prostate 
cancer, and acute myeloid 
leukemia 
(Chase and Cross, 2011; 
Fiskus et al., 2009) 
Cyclin-dependent 
kinases (CDKs) 
Roscovitine Vascular endothelial cells, 
breast cancer, non-small 
cell lung cancer, 
nasopharyngeal cancer 
(Wesierska-Gadek et al., 
2011; Liebl et al., 2011) 
Table 1. Current angiogenic targets and their respective inhibitors.  
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Due to the overwhelming evidence of a pivotal role for VEGF-A in tumor angiogenesis, an 
array of therapeutic agents has been developed against the VEGF-A signaling pathway. In an 
initial study of glioma patients who received bevacizumab and a topoisomerase I inhibitor 
known as irinotecan, 19 out of 29 participants achieved at least a 50% reduction in maximal 
cross-sectional contrast-enhancing areas on magnetic resonance imaging (MRI) (Norden et 
al., 2009). Compared to a radiographic response rate of 5-8% in patients who received 
standard temozolomide treatment, this result was a marked improvement. Moreover, several 
large retrospective studies reported response rates of 25-74% and progression-free survival of 
32-64%. These early studies also demonstrated an additional corticosteroid-sparing effect; the 
majority of patients were able to reduce their corticosteroid doses by 50% or more (Norden et 
al., 2009). Since it first entered routine clinical practice in the United States, however, 
bevacizumab treatment has provided only modest survival benefits overall. Furthermore, 
although a single infusion has been shown to decrease the density of existing 
microvasculature (Willett et al., 2004), bevacizumab primarily targets new blood vessel 
formation. Thus, bevacizumab monotherapy may lack long-term efficacy because it rarely 
targets the mature tumor vasculature that is already established at the time of diagnosis. 
Unfortunately, the molecular mechanism of bevacizumab failure is poorly understood, and 
the absence of effective post-bevacizumab salvage therapies only complicates treatment 
management. Currently, bevacizumab is approved for the treatment of metastatic colorectal 
cancer, non-squamous non-small cell lung cancer, metastatic breast cancer, glioblastoma, and 
metastatic renal cell carcinoma. In June of 2011, however, the FDA’s Oncologic Drugs 
Advisory Committee recommended withdrawing approval of bevacizumab for breast cancer 
due to safety concerns and lack of proven efficacy. Pending the final decision of the 
committee, patients suffering from metastatic breast cancer may soon have to consider other 
therapeutic options (http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab, 
FDA Approval for Bevacizumab, National Cancer Institute, 2011).  
3.1 Mechanisms of resistance 
Emerging data from clinical and pre-clinical investigations indicate that the aggressive 
return to tumor growth after initial response to anti-VEGF-VEGFR therapies is due to a 
variety of drug resistance mechanisms. One mode of resistance to angiogenesis inhibitors is 
adaptive (evasive) resistance. Traditional models of drug resistance focus on the acquisition 
of genetic mutations within the gene that encodes the drug target. Such mutational 
alterations lead to reduced inhibition of the intended disease-promoting factor. In case of 
evasive resistance, the specific vascular target remains inhibited. 
A possible explanation for adaptive resistance, even in the presence of continual drug 
blockade is that the tumor can activate or upregulate alternative pro-angiogenic signaling 
pathways. Evidence for this mechanism in cancer patients was demonstrated in a recent 
clinical investigation. In participants who received the VEGFR inhibitor cediranib, there was 
a temporary response phase followed by relapse. Upon analysis, patient blood levels of 
bFGF were significantly higher during the relapse phase than in the initial stage of response. 
Additional observations revealed increased serum levels of stromal cell-derived factor 1 
(SDF1) and elevated presence of circulating endothelial cells at the time of progression on 
cediranib (Batchelor et al., 2007; Norden et al., 2009). These findings support the hypothesis 
that anti-VEGF pathway inhibitors may be more effective when combined with drugs that 
target other pro-angiogenic factors.  
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In addition to the activation of other angiogenic targets, upregulation of VEGF-A itself can 
significantly enhance tumor resistance to therapy. Recent evidence has demonstrated that 
cytotoxic therapies such as chemotherapy and radiation can induce the production of VEGF-
A in tumors of the lung, breast, colon, and kidney (Volk 2011; Volk 2008). This results in an 
autocrine positive feedback loop that promotes the survival of both tumor cells and 
endothelial cells. Thus, tumor cells can escape programmed cell death through the 
activation of angiogenic signaling in vivo (Volk et al., 2008; Volk et al., 2011).  
A second mechanism that facilitates evasive resistance is the recruitment of bone marrow-
derived cells (BMDCs). BMDCs are recruited in part through increased hypoxia. Hypoxia 
leading to necrosis is one of hallmarks of GBM (Chen et al., 2009), and hypoxic conditions 
often enhance tumor cell resistance to chemotherapy and ionizing radiation. Interestingly, the 
inhibition of VEGF-A with bevacizumab produced a substantial increase in hypoxia-inducible 
factor 1 (HIF1) and CA9, another hypoxia marker (Iwamoto et al., 2009). HIF1 was shown 
to promote GBM neovascularization through the recruitment of pro-angiogenic bone marrow-
derived CD45+ myeloid cells and F4/80+ tumor associated macrophages (Aghi et al., 2006; 
Bergers & Hanahan, 2008; Du et al., 2008). Tumors with little or no HIF1 expression 
displayed few BMDCs, and both angiogenesis as well as tumor growth were significantly 
impaired. Collectively, these observations suggest that anti-angiogenic therapy induces low 
oxygen conditions and accelerates blood vessel formation through BMDC recruitment.  
Although pro-angiogenic BMDCs are important for progression after anti-VEGF-A therapy, 
other cell types, such as pericytes, also contribute to evasive resistance. Pericytes, structural 
support cells that envelop the microvasculature, serve a distinct role of maintaining the 
integrity and functionality of pre-existing blood vessels. Support for this concept is based on 
a variety of investigations which showed that increased PDGF signaling enhances the 
stabilization of tumor blood vessels by recruiting pericytes and promoting pericyte-
endothelial cell interactions (Allt & Lawrenson, 2001; Bergers & Song, 2005; Norden et al., 
2009). In light of these observations, therapeutic strategy of a combined VEGF-VEGFR and 
PDGF-PDGFR inhibition would reduce the resistance to anti-vascular therapy.  
A fourth mechanism of adaptive resistance has gained considerable interest over recent 
years. This form of evasion involves increased invasiveness without the requirement of 
angiogenesis. Following a pharmaceutical blockade of angiogenesis in an orthotopic GBM 
mouse model, glioblastoma cells were able to co-opt the normal vasculature and 
disseminate deep into the brain (Bergers & Hanahan, 2008; Blouw et al., 2003; Du et al., 2008; 
Rubenstein et al., 2000). This phenotype is referred to as perivascular tumor invasion, and it 
allows cells to escape oxygen and nutrient deprivation. Consistent with results from animal 
studies, GBM patients who developed multi-focal recurrence after bevacizumab treatment 
exhibited pro-invasive adaptation as observed by MRI.  
Not all modes of resistance are dependent on adaptation. Some tumors possess an intrinsic, 
pre-existing indifference to anti-angiogenic therapy. In a clinical trial of cediranib, one group of 
GBM patients exhibited transitory improvements while another subset of patients had no 
response. This differential reaction to the same therapy emphasizes the need for biomarkers 
that can accurately predict individual efficacy of anti-VEGF-A therapy from patient to patient. 
3.2 Lack of predictive markers for therapeutic efficacy 
The mechanistic evasion of anti-VEGF-A therapy is further complicated by the lack of 
indicators or predictive markers for therapeutic efficacy. The contrasting response to anti-
angiogenic monotherapy suggests that individual tumors may possess unique angiogenic  
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profiles (Jain, 2005). These profiles consist of informative parameters such as vascular 
permeability, blood flow, interstitial fluid pressure, and the upregulation or downregulation 
of key angiogenic factors. Deciphering these phenotypic codes on an individualized basis 
may allow physicians to better predict and monitor a patient’s response to various anti-
vascular agents. Until this approach of personalized medicine can be achieved, however, a 
growing number of efforts are focused on improving the potency and selectivity of VEGFR 
tyrosine kinase inhibitors.  
4. Modified approach to inhibit the VEGF-VEGFR pathway 
Although targeting the VEGF family presents a range of challenges, the evidence still 
suggests that the VEGF-VEGFR axis is the dominant signal transduction pathway in tumor 
vascularization. Thus, the rationale for using VEGF-A blockade remains quite valid for a 
variety of cancers. One potential obstacle to the therapeutic efficacy of VEGFR inhibition, 
however, is the lack of specificity for VEGFR tyrosine kinases. FDA-approved tyrosine 
kinase inhibitors (TKIs) such as sorafenib and sunitinib inhibit VEGFR TKIs (Table 1), but 
they also potently block signaling through other targets including platelet-derived growth 
factor receptor (PDGFR), stem cell factor receptor (c-kit), and colony-stimulating factor 1 
receptor (CSF1R) (Bhargava & Robinson, 2011). Due to the low selectivity of these multi-
targeted inhibitors, higher dose administration is required to achieve maximal VEGFR 
inhibition. As a result, optimal blockade of VEGF-A receptors is often accompanied by 
increased off-target effects and enhanced toxicity. Adverse events associated with reduced 
target selectivity include hand-foot skin reactions, fatigue, vomiting, diarrhea, hypertension, 
cardiac ischemia, and thyroid dysfunction (Bhargava & Robinson, 2011). Consequently, the 
combined use of TKIs with conventional chemotherapeutic drugs is severely limited. 
4.1 Second-generation VEGFR tyrosine kinase inhibitors 
To circumvent the problems associated with off-target toxicities, a new initiative is 
underway to develop second-generation VEGFR TKIs that exhibit extreme potency and 
elevated selectivity. One of the most promising candidates is a pan-VEGFR antagonist 
known as tivozanib (Table 1). Demonstrating picomolar potency to VEGFR-1, VEGFR-2, 
and VEGFR-3, tivozanib significantly increased progression-free survival from 6.2 months to 
12.1 months in patients with renal cell carcinoma (Bhargava & Robinson, 2011). 
Furthermore, it is the first TKI to be safely combined with a mammalian target of rapamycin 
(mTOR) inhibitor and is currently involved in phase I studies with other therapeutic agents 
in both metastatic breast cancer and advanced colorectal cancer. 
Tivozanib is not alone in this subset of novel, selective TKIs. Axitinib (Table 1), a small 
molecule inhibitor of all known VEGFRs, also demonstrates increased efficacy as both 
monotherapy and in combination with chemotherapy. Further clinical evaluation is being 
performed to assess the effects of axitinib in lung cancer, metastatic breast cancer, pancreatic 
cancer, and advanced gastric cancers (Bhargava & Robinson, 2011). Overall, collective data 
generated from clinical studies indicate that second-generation TKIs are generally associated 
with lower off-target toxicities, more potent and less toxic than traditional inhibitors of 
receptor tyrosine kinases. 
4.2 Inhibition of the protein kinase D family 
Since the tolerability of novel TKIs is still unknown for multiple tumor types, another 
potential approach to control the angiogenic process is to target the VEGF-VEGFR pathway 
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through indirect mechanisms of action. In this modified approach to vascular inhibition, 
therapeutic strategies are designed to block the downstream effectors of VEGF-A-induced 
angiogenic signaling. Recent investigation of tumor blood vessel formation revealed a key 
role for protein kinase D1 (PKD1) in VEGF-A signaling (LaValle et al., 2010).  
A novel serine/threonine protein kinase, PKD1 mediates VEGFR-2-stimulated endothelial 
cell proliferation through the activation of extracellular signal-regulated kinases 1 and 2 
(ERK 1/2) (Ha & Jin, 2009). Moreover, the subcutaneous implantation of matrigel plugs in 
vivo showed that functional PKD1 activity was necessary for VEGF-A-induced angiogenesis. 
The ability of PKD1 to promote angiogenesis is due in part to class IIa histone deacetylase 
(HDAC) activity. Important for chromatin modifications and repression of gene expression, 
HDAC5 and HDAC7 enzymes are direct targets of PKD1-dependent phosphorylation in 
endothelial cells stimulated with VEGF-A. Upon phosphorylation of Ser259/498 in HDAC5 
and Ser178, Ser344, and Ser479 in HDAC7, HDAC translocation from the nucleus to the 
cytoplasm promotes the expression of myocyte enhancer factor-2 (MEF2)-dependent genes 
(Ha & Jin, 2009). Through an unidentified mechanism, the PKD1-HDAC pathway 
eventually leads to angiogenic gene expression, endothelial cell migration, tubule formation, 
and microvascular sprouting.  
As a frequently upregulated isoform in pancreatic and prostate cancer, PKD1 has 
understandably become an attractive target for chemical inhibition. Perhaps the most 
promising compound of PKD inhibitors is CRT0066101 (Table 1) (LaValle et al., 2010). A 
pan-inhibitor of PKD1, PKD2, and PKD3, CRT0066101 is orally available and substantially 
suppresses the growth of pancreatic tumors in an orthotopic mouse model. Unfortunately, 
information regarding the three-dimensional (3D) structure of PKD is incomplete. 
Therefore, the present lack of structure-based drug design hinders the optimization of 
current anti-PKD compounds.  
4.3 Rho GTPase signaling 
Other downstream mediators of VEGF-VEGFR signaling are also generating interest as 
proponents of tumor angiogenesis. One particular signaling cascade, the Rho GTPase 
pathway, has recently been implicated in several phases of angiogenesis such as vascular 
permeability, endothelial cell migration, proliferation, and lumen formation. Functioning as 
molecular gatekeepers, this subfamily of the Ras superfamily of small GTPases is activated 
by VEGF-A binding to VEGFR-2 in endothelial cells (van der Meel et al., 2011).  
This ligand-receptor interaction initiates the recruitment of proteins like c-Src or 
phospholipase C beta 3 (PLC3) to the phosphorylated tyrosine residues of the VEGF-A 
receptors. Following this initial recruitment, Rho GTPases like Rac1, RhoA, and Cdc42 
become active and subsequently promote tumor vascularization through destabilization of 
endothelial barrier integrity, enhanced migration, proliferation, and tubule formation (van 
der Meel et al., 2011).  
Attempts to disrupt Rho GTPase signal transduction frequently involve the use of Rho-
associated coiled-coil-forming kinase (ROCK) inhibitors. One such inhibitor, HA1077 (fasudil) 
(Table 1), can effectively block migration, cellular viability, and tubule formation in VEGF-A-
stimulated vascular endothelial cells. Interestingly, treatment with fasudil attenuates the 
anchorage-dependent growth of breast cancer cells and significantly reduces tumor burden in 
an experimental model of murine lung metastasis (van der Meel et al., 2011). 
Another compound, NSC23766 (Table 1), is a small-molecule inhibitor of Rac1. Similar to 
ROCK inhibitors, NSC23766 attenuates cell proliferation as well as tumor growth. In 
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contrast to the effects of pharmacological inhibition of Rac1, however, depletion of Rac1 in 
the tumor endothelium of adult wild-type mice had no effect on angiogenesis and revealed 
a complete lack of tumor growth suppression (van der Meel et al., 2011). In order to 
reconcile such conflicting outcomes, more information is needed regarding the regulation 
and downstream signaling of Rho GTPases. Unraveling the intricate relationships between 
different members of this signaling family may uncover the necessary combinations of 
druggable targets that will be most effective for clinical use. 
5. Novel molecular targets for anti-angiogenesis therapy 
For years, the VEGF-A signaling pathway has been the primary target of vascular inhibition. 
Due to the emerging complications of resistance, however, efforts to discover new molecular 
targets have increased. We have previously described the role of cytosolic phospholipase A2 
(cPLA2) in radiation-induced signal transduction in human lung cancer and ovarian 
carcinoma (Linkous et al., 2009; Schulte et al., 2011; Yazlovitskaya et al., 2008). Following the 
observation that cPLA2 promotes the survival of vascular endothelium, we have also 
identified this cytoplasmic enzyme as a fundamental component of tumor angiogenesis 
(Linkous et al., 2010).  
5.1 Cytosolic phospholipase A2 promotes tumor angiogenesis 
In cPLA2-deficient mice, a syngeneic glioblastoma cell line (GL261) failed to form tumors 
even after 2 months post-injection. By contrast, their cPLA2-wild type counterparts 
displayed a tumor take rate of 100% (Figure 3). In similar experiments, Lewis lung 
carcinoma (LLC) cells did form tumors in cPLA2-deficient mice; however, they were 
dramatically smaller than tumors in cPLA2-wild type mice.  
To determine the effects of cPLA2 deficiency on tumor vascularity, LLC tumors from 
cPLA2α+/+ and cPLA2α-/- mice were sectioned and examined for microvascular density 
using an antibody against von Willebrand Factor (vWF), a known vascular endothelial cell 
marker. Immunohistochemical examination revealed decreased blood vessel formation and 
increased areas of necrosis in tumors from cPLA2α-/- mice, thus implicating cPLA2 as an 
important factor for tumor formation, growth and maintenance (Linkous et al., 2010).  
Tumor vascularization requires not only capillary formation, but also the maturation of 
endothelial-lined blood vessels. This process of vessel maturation is dependent on the 
functions of cells known as pericytes. Previously regarded as inactive scaffolding 
components, pericytes are now recognized for their ability to coordinate intercellular 
signaling with endothelial cells and other elements of the blood vessel wall to prevent 
leakage. As necessary components in vessel stabilization, pericytes maintain vessel integrity 
and aid in the assembly of extracellular matrix (ECM) components. To determine whether 
cPLA2 is involved in tumor blood vessel maturation, LLC tumor sections were co-stained 
with antibodies to vWF and to two established pericyte markers (alpha-smooth muscle actin 
(α-SMA) and desmin) used to detect stages of vascular development (Figure 4). Results from 
α-SMA immunofluorescence demonstrated significant pericyte coverage of the tumor 
vasculature in LLC tumors from cPLA2α+/+ mice. In tumors from cPLA2α-/- mice, however, 
vessel-encircling pericytes were undetectable. Since α-SMA expression may be dependent 
upon the maturation stage of pericytes, tumor sections were also examined for the presence 
of desmin, which is expressed by both mature and immature pericytes. Although desmin 
was detected in tumor vasculature from cPLA2α+/+ mice, no desmin-positive cells were 
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observed within tumor blood vessels from cPLA2α-/- mice (Linkous et al., 2010). These 
marked differences in pericyte coverage suggest that, in addition to its role in endothelial 
cell function, cPLA2 may also be responsible for pericyte recruitment and required vessel 
maturation. Such findings implicate a novel pro-angiogenic role for cPLA2 in the tumor 
microenvironment.  
 
 
Fig. 3. GL261 tumor growth in cPLA2α-deficient mice (Linkous et al., 2010). 
GL261 cells were injected subcutaneously into the hind limbs of cPLA2α+/+ and cPLA2α-/- 
C57/BL6 mice (n = 6–7 mice per group). Tumor volume was measured using power 
Doppler sonography at 48-hour intervals beginning 1 week after injection and ending when 
tumors reached a volume of 700 mm3 or a diameter of 15 mm). Shown are the mean GL261 
tumor volumes. Days 11–39: P < .001 (longitudinal analysis of least squares means). Error 
bars correspond to 95% confidence intervals.  
Since cPLA2 is responsible for the production of bioactive lipid mediators, LPC, AA, and 
lysophosphatidic acid (LPA), we wanted to determine which of these products contributes 
to the promotion of vascular endothelial cell migration. Although the restoration of LPC, 
LPA, and AA alone resulted in increased migration, the most pronounced effect was 
observed with the addition of LPC + LPA or LPC + AA to primary endothelial cells isolated 
from cPLA2α-/- mice (Linkous et al., 2010). These results indicate that, in addition to AA and 
LPA, which regulate endothelial cell migration (Folkman, 2001; Herbert et al., 2009; Kishi et 
al., 2006; Ptaszynska et al., 2008), the less-characterized LPC pathway may also play a 
significant role in this process. In addition, the most pronounced increase in cellular 
proliferation was observed in cPLA2α-/- cells treated with a combination of LPC and LPA 
(Linkous et al., 2010). These data demonstrate a key role for cPLA2 in endothelial cell 
proliferation and indicate that the lysophospholipids, LPC and LPA, may serve as effectors 
for this stage of angiogenesis. 
Due to its functional responsibility in inflammation, radiation signaling, and angiogenesis, 
cPLA2 has become an attractive target for chemical inhibition. Two of the most commonly  
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Fig. 4. Pericyte coverage of blood vessels in tumors from cPLA2α+/+ and cPLA2α-/- mice 
(Linkous et al., 2010).  
Formalin-fixed Lewis lung carcinoma (LLC) tumors from cPLA2α+/+ (upper rows) and 
cPLA2α-/- (lower rows) were sectioned and co-stained with antibodies against von 
Willebrand factor (left panels) and either a-smooth muscle actin (middle panels, a) or 
desmin (middle panels, b) and counterstained with DAPI (4′,6-diamidino-2-phenylindole). 
a) Representative micrographs of immunofluorescence staining for von Willebrand factor 
(green), a-smooth muscle actin (red), and DAPI (blue) in tumors from cPLA2α+/+ and 
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cPLA2α-/- mice (at 40× magnification). Right panels present merged immunofluorescence 
staining of von Willebrand factor and cells positive for a–smooth muscle actin (yellow).  
b) Representative micrographs of immunofluorescence staining for von Willebrand factor 
(green), desmin (red), and DAPI (blue) in tumors from cPLA2α+/+ and cPLA2α-/- mice  
(at 40× magnification). Right panels present merged immunofluorescence staining of von 
Willebrand factor and cells positive for desmin (yellow). 
used cPLA2 inhibitors are arachidonyltrifluoromethyl ketone (AACOCF3) and methyl 
arachidonyl fluorophosphonate (MAFP) (Table 1) (Yazlovitskaya et al., 2008). AACOCF3 
is a potent and cell-permeable trifluoromethyl ketone analog of arachidonic acid. Nuclear 
magnetic resonance studies have shown that the carbon chain of AACOCF3 binds in a 
hydrophobic pocket of cPLA2 and the carbonyl group of AACOCF3 forms a covalent bond 
with serine 228 in the enzyme active site (Farooqui et al., 2006). This cPLA2 inhibitor has 
been used to study the role of cPLA2 in platelet aggregation, inflammation-associated 
apoptosis, and the radiosensitivity of vascular endothelial cells (Yazlovitskaya et al., 
2008). Combined with radiation, AACOCF3 was also demonstrated to significantly inhibit 
tumor growth and tumor vascularity in the mouse models of lung and ovarian cancers 
(Linkous et al., 2009; Schulte et al., 2011). Similar to AACOCF3, MAFP is also a powerful 
inhibitory agent, however, this irreversible drug inhibits both the calcium-dependent and 
calcium-independent (iPLA2) forms of the enzyme (Farooqui et al., 2006). Other agents 
including pyrrolidine-based inhibitors have also been used extensively to block PLA2 
enzymatic activity. Nevertheless, like other pyrrolidine-containing compounds, this class 
of drugs is non-specific and attenuates the activity of cPLA2- and iPLA2- (Farooqui et 
al., 2006). Recent attempts to improve the specificity of these compounds have unveiled 
new indole-based candidates for cPLA2-targeted therapy (McKew et al., 2006). Based on 
promising preliminary results, our laboratory synthesized a compound known as 4-[2-[5-
Chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]-ethoxy]benzoic acid (CDIBA) (Table 
1) (Linkous et al., 2010). Shown to potently target cPLA2- and substantially attenuate 
arachidonic acid release in a wide variety of enzymatic and cell-based assays, CDIBA 
treatment inhibited capillary tubule formation, migration, and cellular proliferation in 
tumor vascular endothelial cells (Linkous et al., 2010). Furthermore, in heterotopic 
glioblastoma and lung cancer tumor models, mice treated with CDIBA exhibited delayed 
tumor growth and reduced tumor volume (Linkous et al., 2010). Accordingly, 
pharmaceutical companies are now focused on the continual optimization of these novel 
cPLA2 inhibitors for clinical use.  
5.2 Autotaxin and lysophosphatidic acid signaling  
Advances in anti-angiogenic therapy are not solely dependent on the discovery of 
endothelial-associated targets, however. Indeed, as in the case of VEGF-A, tumor cells also 
secrete soluble inducers of angiogenesis. An excellent example of this paracrine effect can 
be found in the previously mentioned lipid second messenger, LPA. Shown to stimulate 
cell proliferation, migration, and survival, LPA has been implicated in the progression of 
many tumors including lung cancer, hepatocellular carcinoma, and epithelial ovarian 
cancer (Ptaszynska et al., 2008; Ren et al., 2006). LPA signaling is primarily mediated 
through classic G protein-coupled receptors that belong to the endothelial differentiation 
gene (EDG) family (LPA1/EDG-2, LPA2/EDG-4 and LPA3/EDG-7). LPA can also exert its 
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role through other receptors such as, LPA4/GPR23, LPA5/GPR92, GPR87 and P2Y5 (Aoki 
et al., 2008). There are two major pathways of LPA production: 1) phosphatidic acid 
generated by phospholipase D or diacylglycerol kinase is subsequently converted to LPA 
by cPLA2; 2) lysophospholipids generated by cPLA2 (such as LPC) are subsequently 
converted to LPA by lysophospholipase D, also known as autotaxin (ATX) (Aoki et al., 
2008; Hama et al., 2004; Jansen et al., 2005; Tokumura et al., 1986; Umezu-Goto et al., 2002). 
Unlike other members of the ectonucleotide pyrophosphatase and phosphodiesterase 
(NPP) family of enzymes, ATX possesses robust lysophospholipase D activity (Jansen et al., 
2005; Ptaszynska et al., 2008). Initially purified from melanoma cells as a potent 
chemoattractant (Stracke et al., 1992), this 103 kDa secreted protein is upregulated in a 
variety of malignancies and has been shown to stimulate cell proliferation and enhance 
tumor invasion and metastasis (Tanaka et al., 2006).  
While ATX can be produced by endothelium, the majority of ATX is generated and secreted 
by a variety of tumor cells. As the primary enzyme involved in the production of LPA, ATX 
has recently sparked interest for its potential role in the development and progression of 
ovarian cancer. As the fifth leading cause of death in American women, ovarian tumors are 
known to produce larger quantities of LPA than nonmalignant cells (Fang et al., 2002) Due 
to the high substrate levels of LPC found in peritoneal fluids from patients with ovarian 
cancer, the observed increase in LPA is attributed to elevated ATX activity (Schulte et al., 
2011; Tokumura et al., 2007). Moreover, expression of LPA receptors was found to 
determine tumorigenicity and aggressiveness of ovarian cancer cells. Our laboratory and 
others have recently demonstrated that ATX and LPA signaling may contribute to the 
resistance of ovarian carcinoma to cytotoxic therapies such as cisplatin and ionizing 
radiation (Schulte et al., 2011). Based on these results, it remains conceivable that LPA 
generated from LPC hydrolysis could bind to LPA receptors on vascular endothelium as 
well as those found on tumor cells.  
Correspondingly, a cooperation of both VEGF-A and ATX was discovered in the regulation 
of endothelial cell migration (Ptaszynska et al., 2010). Knockdown of ATX expression 
prevented endothelial cell migration in response to stimulation with LPC, LPA, and VEGF-
A. Moreover, the genetic silencing of ATX resulted in a concomitant reduction in the mRNA 
levels of LPA receptors (Ptaszynska et al., 2010). Taken together, these data suggest that 
ATX regulates the expression of LPA receptors that are necessary for VEGF-A- and 
lysophospholipid-induced angiogenesis. Thus, pharmacological inhibition of both ATX and 
LPA may serve as an effective method to reduce tumor vascularization. 
Since ATX is a member of the alkaline phosphatase superfamily of metalloenzymes, initial 
medicinal chemistry efforts focused on metal chelaters as ATX inhibitors (Hoeglund et al., 
2010). The chelaters reduce the metal-ion stimulation of ATX activity by competing with 
active site histidine and aspartic acid residues for divalent metal ions (Clair et al., 2005; 
Hoeglund et al., 2010; Tokumura et al., 1998). Not surprisingly, metal ion chelation is 
considered a relatively insensitive and non-specific method of ATX inhibition (Hoeglund et 
al., 2010). The library of ATX inhibitors has since expanded to include both non-lipid small-
molecule inhibitors as well as analogs of bioactive lipids. Both categories of drugs are 
promising in vitro, although the non-lipid ATX inhibitors are more compliant with the 
characteristic parameters often found in orally bioavailable drugs (Hoeglund et al., 2010; 
Keller et al., 2006). Furthermore, these non-lipid compounds exhibit enhanced specificity for 
ATX without affecting other members of the NPP family (Hoeglund et al., 2010). Despite the 
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identification of new inhibitory agents, the lack of information regarding the three-
dimensional structure of ATX is impeding drug discovery (Parrill & Baker, 2010). Until the 
structural details of the enzyme are publicly disclosed, current medicinal chemistry efforts 
are focused on other ATX-associated targets such as LPA and the subsequent LPA receptors. 
One of the most common approaches to disrupt LPA signaling is to use LPA derivatives as 
selective receptor antagonists (Im, 2010). Many of these individual derivatives can exert a 
combined antagonistic effect against more than one LPA receptor. A primary example of 
this can be found in the –bromomethylene phosphonate analog of LPA known as BrP-LPA 
(Table 1). As a pan-antagonist of LPA1-4, BrP-LPA has been shown to significantly reduce 
the migration, invasion, vascularity and tumor volume in mouse models of breast cancer 
and non-small cell lung cancer (Im, 2010; Prestwich et al., 2008; Xu & Prestwich, 2010; Zhang 
et al., 2009). Moreover, this potent and efficacious inhibitor also blocks over 98% of ATX 
activity at micromolar concentrations (Zhang et al., 2009). Such results suggest that the use 
of multi-target antagonists may provide the best strategy for the abrogation of ATX-LPA 
signal transduction.  
5.3 Enhancer of Zeste homolog 2  
The combined approach to anti-vascular therapy is becoming increasingly attractive as the 
tumor-endothelial cell interaction is deciphered. For instance, a paracrine relationship 
between VEGF-A and the enhancer of Zeste homolog 2 (EZH2) was just identified (Lu et al., 
2010). EZH2 is a member of the polycomb-group (PcG) proteins and has intrinsic histone 
methyl transferase activity. Histone methylation is a common method of epigenetic gene 
regulation and is typically associated with transcriptional repression. Armed with this 
ability to inhibit transcription, EZH2 is frequently implicated in tumor progression and 
metastatic disease. A recent investigation revealed that VEGF secreted from human 
epithelial ovarian cancer cells could directly increase EZH2 mRNA levels in vascular 
endothelial cells (Lu et al., 2010). Elevated tumoral and endothelial EZH2 was also observed 
in more than 60% of available epithelial ovarian cancer samples. Furthermore, heightened 
levels of EZH2 were associated with high-grade disease and were predictive of poor overall 
survival. In a study to determine the mechanism behind such a dismal clinical outcome, Lu 
and colleagues investigated the relationship between EZH2 and the secreted protein, 
vasohibin1 (VASH1). Induced by VEGF-A stimulation, VASH1 is a newly identified 
negative regulator of angiogenesis. Interestingly, increased EZH2 resulted in the 
methylation and subsequent inactivation of VASH1 (Lu et al., 2010). Considering the 
complications of intrinsic or acquired resistance to anti-VEGF-A monotherapy, a 
combinatorial strategy that focuses on vascular and tumor-specific targets may provide the 
greatest efficacy. 
Despite growing evidence of the relationship between EZH2 and tumorigenesis, there are 
currently no clinically available therapies that directly target histone methylation (Chase & 
Cross, 2011). Some experimental studies on the inhibition of EZH2 activity have been 
performed, however. Using a carbocyclic adenosine analog known as 3-deazaneplanocin 
(DZNep) (Table 1), several groups have demonstrated depletion of EZH2 levels and 
reduced proliferation in breast cancer and prostate cancer cells (Chase & Cross, 2011). 
Futhermore, treatment with DZNep induced apoptosis in acute myeloid leukemia (AML) 
cells and significantly prolonged the survival of mice implanted with AML cells (Fiskus et 
al., 2009). Similar to other non-specific inhibitors, DZNep affects targets other than EZH2 
www.intechopen.com
 
Tumor Angiogenesis 
 
266 
(Chase & Cross, 2011; Fiskus et al., 2009; Yamaguchi et al., 2010). Although EZH2 is the 
catalytic subunit of the polycomb repressive complex 2 (PRC2), it is accompanied by other 
components including SUZ12, EED, and YY1. Consequently, treatment with DZNep results 
in the depletion of each of these PRC2 complex proteins and blocks the associated histone 
H3 lysine 27 methylation (Chase & Cross, 2011; Fiskus et al., 2009; Yamaguchi et al., 2010). 
Therefore, DZNep may interfere with normal physiological processes that require methyl 
transfer.  
5.4 Cyclin-dependent kinases  
Cyclin-dependent kinases (CDKs) have long been recognized for their involvement in the 
regulation of cell cycle transitions and cellular proliferation. As members of the serine-
threonine kinase family, CDKs bind to regulatory proteins called cyclins and phosphorylate 
protein substrates on serine and threonine amino acid residues. Given the importance of cell 
cycle management in the prevention of uncontrolled cell growth, studies that shed light on 
the function of CDKs in tumorigenesis have gained recent momentum. A number of small-
molecule inhibitors have been developed to alter the CDK deregulation that is frequently 
observed in human cancers (Baker, 2010; Liebl et al., 2011; Liebl et al., 2010). Success with 
one of the earliest CDK inhibitors, olomoucine, led to the widespread search for more 
specific compounds that would preclude aberrant CDK activity in tumors. To date, multiple 
CDK inhibitors have demonstrated anti-proliferative effects in cultured and xenografted 
myeloma, leukemia, colon cancer, lung cancer, and breast cancer cells (Baker, 2010; Liebl et 
al., 2011; Liebl et al., 2010). Recently, the CDK inhibitor roscovitine (Table 1), was shown to 
arrest human estrogen receptor alpha (ER-) positive MCF-7 breast cancer cells in the G(2) 
phase of the cell cycle and induce p53-dependent apoptosis (Wesierska-Gadek et al., 2011). 
Based on its anti-cancer activity both in vitro and in vivo, roscovitine is being evaluated in 
phase 2 clinical trials for the treatment of non-small cell lung cancer and nasopharyngeal 
cancer (Baker, 2010; Liebl et al., 2011; Liebl et al., 2010). Aside from its ability to impede 
tumor cell division, anti-angiogenic properties have also been discovered for this CDK 
inhibitor. Surprisingly, only a few prior reports have denoted a role for CDKs in tumor 
angiogenesis. To understand the molecular basis of these cell cycle and transcriptional 
regulators in tumor blood vessel formation, Liebl et al., assessed the effects of CDK 
inhibition in human umbilical vein endothelial cells (HUVEC) (Liebl et al., 2011; Liebl et al., 
2010). In response to treatment with roscovitine, endothelial migration and tubule formation 
was significantly reduced. Furthermore, the chemical inhibition of CDKs greatly impaired 
endothelial cell sprouting from mouse aortic rings and abolished VEGF-A-induced vessel 
formation in the chorioallantoic membrane assay (Liebl et al., 2011; Liebl et al., 2010). While 
roscovitine does not selectively inhibit one specific CDK, the knockdown of cyclin-
dependent kinase 5 (CDK5) revealed that roscovitine might exert its anti-vascular properties 
through a CDK5-dependent pathway (Liebl et al., 2011; Liebl et al., 2010). Other CDKs such 
as CDK4 have also been reported as plausible contributors to tumor vascularization. In a 
murine model of intestinal tumors, constitutive activation of CDK4 was shown to enhance 
tumor blood vessel formation and increase the expression of E2F target proteins involved in 
angiogenesis and proliferation (Abedin et al., 2010; Baker, 2010). Taken together, these 
findings suggest that the pharmacological inhibition of CDKs, either alone or in 
combination, may provide a novel method of vascular destruction (Baker, 2010; Liebl et al., 
2011; Liebl et al., 2010).  
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6. Conclusion 
Current attempts to disrupt the complex process of tumor blood vessel formation are 
predominantly focused on the VEGF-VEGFR signaling pathway. Although clinically proven 
to inhibit VEGF-A and its receptors, these pharmacologic agents are selective, but not 
specific. Consequently, many of the approved inhibitors also impair other molecular targets, 
thus, leading to increased toxicity. To reduce toxicity complications and augment the 
destruction of the tumor vascular network, an active search for new inhibitory agents has 
begun. In recent years, the emergence of several VEGF-VEGFR angiogenesis inhibitors has 
enhanced the clinical outcome for multiple tumors. It is important to note, however, that 
many of these pharmacologic agents resulted in transitory improvements followed by 
increased tumor resistance and metastasis. The observed resistance may be partially 
explained by the complex network of signal transduction that constitutes the angiogenic 
process. The frequent interconnectivity of these signaling pathways often results in 
redundancy during the formation of tumor blood vessels. As a result, when one pro-
angiogenic target is inhibited, other molecules can be activated so that the requirement for 
vascularization is once again fulfilled. Furthermore, therapeutic pressure from 
chemotherapy and ionizing radiation can promote a VEGF-A-dependent autocrine loop 
which protects tumor cells and endothelial cells from cytotoxicity. Thus, the most effective 
therapeutic strategy may be to combine conventional treatment regimens with therapies that 
target multiple angiogenic pathways. 
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